Malaria parasite plasmepsins: More than just plain old degradative pepsins

Armiyaw S. Nasamu  
Washington University School of Medicine in St. Louis

Alexander J. Polino  
Washington University School of Medicine in St. Louis

Eva S. Istvan  
Washington University School of Medicine in St. Louis

Daniel E. Goldberg  
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation
https://digitalcommons.wustl.edu/open_access_pubs/9282

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Malaria parasite plasmepsins: More than just plain old degradative pepsins

Plasmepsins are a group of diverse aspartic proteases in the malaria parasite *Plasmodium*. Their functions are strikingly multifaceted, ranging from hemoglobin degradation to secretory organelle protein processing for egress, invasion, and effector export. Some, particularly the digestive vacuole plasmepsins, have been extensively characterized, whereas others, such as the transmission-stage plasmepsins, are minimally understood. Some (e.g. plasmepsin V) have exquisite cleavage sequence specificity; others are fairly promiscuous. Some have canonical peptic-like aspartic protease features, whereas others have unusual attributes, including the nepenthesin loop of plasmepsin V and a histidine in place of a catalytic aspartate in plasmepsin III. We have learned much about the functioning of these enzymes, but even remains to be discovered about their cellular roles and even their mechanisms of action. Their importance in many key aspects of parasite biology makes them intriguing targets for antimalarial chemotherapy. Further consideration of their characteristics suggests that some are more viable drug targets than others. Indeed, inhibitors of invasion and egress offer hope for a desperately needed new drug to combat this nefarious organism.

Malaria is caused by protozoan organisms of the genus *Plasmodium*. The disease is transmitted by infected female *Anopheles* mosquitoes, which inject salivary gland sporozoites into the skin during bloodfeeding. These sporozoites make their way to the liver, replicate, and differentiate into infective merozoites. The merozoites egress into the bloodstream, where they invade red blood cells (RBCs) and set up a continuous intraerythrocytic cycle that amplifies their population, often to overwhelming numbers. Some differentiate into sexual-stage parasites, to be taken up by the next mosquito and develop in the mosquito gut, ultimately migrating to the salivary glands for spread to the first to have a crystal structure (6, 7). A poor correlation between ability of a compound to kill parasites and potency against isolated enzyme (8) suggested that digestive vacuole plasmepsin inhibition was not the mode of parasite killing for these molecules. This ultimately led to the realization that there must be other targets, likely other aspartic proteases, whose inhibition is responsible for the antiplasmodial properties. The search for these targets has uncovered myriad functions for these enzymes. Plasmepsins are involved in bulk protein degradation, secretory protein maturation, egress, invasion, endothelial adherence, and perhaps other processes. A number have been the subject of serious efforts as targets for drug development.

Plasmepsins (Fig. 2) belong to an ancient family of aspartic proteases—the A1 or peptic-like family—that is widespread throughout eukaryotes. Among the 10 plasmepsins, the most closely related are the digestive vacuolar plasmepsins, PM I–IV. These proteases are spread across just 16 kilobases of chromosome 14 and share 50–70% amino acid identity. Outside of *P. falciparum* and related primate-infecting species, these proteases are represented by a single plasmepsin, called PM IV in *Plasmodium* and ASP1 in the related apicomplexan *Toxoplasma gondii* (9). PM V is the most diverged plasmepsin, sharing 19–23% amino acid identity with the other plasmepsins. Its structure is bolstered by seven disulfide bonds (compared with two in PM I–IV), bringing it into a separate aspartic protease subfamily from the other plasmepsins—subfamily A1B, with type member Nep1 of the pitcher plant *Nepenthesia* (10). Other apicomplexans also have a single PM V ortholog (ASP5 in *Toxoplasma gondii*), except for cryptosporidia, which have three (9). Regarding transmission-stage plasmepsins, PM VI and VIII form a clade, sharing 36% amino acid identity with each other. Each has a little-studied ortholog in *T. gondii* (ASP2 and ASP4 respectively). PM VII has distant homology to PM VI and VIII (31% identity); its uncharacterized *Toxoplasma* ortholog is ASP6. PM IX and X share 37% amino acid identity. Although the two are distinct across *Plasmodium* and exist on different chromosomes, they are represented by a single *T. gondii* aspartic protease, ASP3.

A note on nomenclature: In the literature, plasmepsins are denoted with Roman numerals or Arabic numerals, with or without a space before the number, and plasmepsin III is known as histo-aspartic protease or HAP or PM III (or PMIII or PM 3). We suggest going back to a convention initiated in early publications of having Roman numerals after a space. We further suggest that HAP be referred to as PM III for consis-
tency with the other plasmepsins and because its His32 has not been shown to be catalytic. Also, HAP is the name for a gamete fusion protein. Using PM III allows the digestive vacuole plasmepsins in aggregate to be called PM I–IV without ambiguity. An argument for the space before the Roman numeral is that PM V is often referred to in discussions of sending proteins out to the parasitophorous vacuolar membrane or PVM, and PMV gets confusing in this context. These issues are ultimately for those concerned with nomenclature to weigh in on, but in this review, we will use our preferred convention.

There are also nonplasmepsin aspartic proteases in the Plasmodium genome (see “Other aspartic proteases”). The microgametocyte surface protein (MiGS) has homology to PM V (21% amino acid identity and shared transmembrane domain; 17–20% to other plasmepsins). Additional aspartic proteases in the Plasmodium genome—signal peptide peptidase (SPP) and DNA damage-inducible 1 (Ddi1)—are quite distinct from the plasmepsins. SPP is a presenilin-type aspartic protease (family A22). Ddi1 (family A28) is the most diverged from the other aspartic proteases. It possesses a single catalytic aspartate and likely homodimerizes to complete the active site, an unusual architecture among eukaryotic aspartic proteases (although common to retroviral aspartic proteases).

Here, we review the state of knowledge on the plasmepsins, noting outstanding questions in the field. This review will focus on P. falciparum, the deadliest human malaria parasite, for which extensive biological studies have been performed; reference to other species will be made as relevant. Study of the
diverse plasmepsins has taught us much about the biology of the malaria parasite and a little about the protein chemistry of aspartic proteases and is pointing the way to exciting new inhibitors that are being developed as antimalarial chemotherapeutic agents.

Digestive vacuole plasmepsins: Plasmepsins I–IV

Intraerythrocytic malaria parasites digest hemoglobin at a prodigious rate (11). This catabolic process provides nutrients for the parasite and has been proposed to maintain osmotic balance in the host cell (11–13). Hemoglobin is ingested by Plasmodium through an endocytic structure called the cytostome, which spans the plasma membrane and the vacuolar membrane surrounding the parasite (Fig. 3A) (14, 15). Hemoglobin-containing vesicles pinch off and fuse with the digestive vacuole, an acidic organelle containing 10 proteases that function in a semi-ordered pathway to degrade the hemoglobin to small peptides and amino acids (16–18) (Fig. 3B). Some of these peptides are thought to be exported out of the digestive vacuole for terminal degradation in the cytoplasm (17, 19, 20).

The degradative process may start in transport vesicles and commences early after erythrocyte invasion (14). Heme is liberated by degradation and most is sequestered as a crystalline lattice of β-hematin dimers called hemozoin (21). Some antimalarial drugs like chloroquine appear to function by blocking heme sequestration, leading to toxic heme build-up (22). A network of proteins implicated in the hemoglobin endocytosis process has recently been defined and includes the artemisinin-resistance protein Kelch13 (23). This finding has yielded a cogent mechanistic explanation for artemisinin resistance. Mutations in Kelch13 and other proteins cause decreased hemoglobin ingestion and digestion, yielding less artemisinin-activating heme (23, 24).

Discovery

Involvement of aspartic proteases in hemoglobin digestion was suspected nearly 50 years ago from the characterization of crude parasite extracts (25, 26). The older literature contains numerous reports of hemoglobin-degrading acidic protease activities in various Plasmodium species, and some were shown to be blocked by the canonical aspartic protease inhibitor pepstatin A (25–34). Their cellular roles remained unclear until studies on isolated digestive vacuoles showed the ability to degrade hemoglobin (16, 35), and protease inhibitor profiling of hemoglobinase activity from highly purified digestive vacuoles revealed a central role for aspartic proteases (16). Soon thereafter, two aspartic proteases (now called PM I and II) were purified from large-scale digestive vacuole preparations and shown to cleave hemoglobin (1, 2, 36). After release of the P. falciparum genome, two more plasmepsins were shown to be present in the digestive vacuole, PM III and PM IV (4, 5, 37).
Cysteine protease inhibitors are more potent in vitro vacuole plasmepsins and between these enzymes and the cysteine proteases called falcipains. Knockouts of individual \textit{P. falciparum} plasmepsins have minor effects on parasite growth in culture (38–41), whereas knockout of all four leads to a substantial growth defect, although the knockout line is still viable (42). Knockout of the single \textit{Plasmodium berghei} digestive vacuole plasmepsin yields a similar phenotype in the mouse sensitized parasites to piperaquine, suggesting that this amplification is due to a second subunit activation (59). However, increasing PM II/PM III levels is not sufficient to impart piperaquine resistance in laboratory strains, hinting at the possibility that it could be a zinc metalloprotease, native enzyme was not inhibited by EDTA (5), and only the dimeric

**Function**

There is extensive functional redundancy among the digestive vacuole plasmepsins and between these enzymes and the cysteine proteases called falcipains. Knockouts of individual \textit{P. falciparum} plasmepsins have minor effects on parasite growth in culture (38–41), whereas knockout of all four leads to a substantial growth defect, although the knockout line is still viable (42). Knockout of the single \textit{Plasmodium berghei} digestive vacuole plasmepsin yields a similar phenotype in the mouse sensitized parasites to piperaquine, suggesting that this amplification is due to a second subunit activation (59). However, increasing PM II/PM III levels is not sufficient to impart piperaquine resistance in laboratory strains, hinting at the possibility that it could be a zinc metalloprotease, native enzyme was not inhibited by EDTA (5), and only the dimeric
apoenzyme structure had active site zinc (67), whereas it is the monomer that is active (70). A proposal was put forth that Asp^{32} acts as an acid as well as a base, but this model was based on a profound stabilization (several orders of magnitude) by His^{52} (75). Perhaps a different residue could be the stabilizer; Lys^{78} has been suggested (73). Weighing on this debate is the fact that the properties of native enzyme and the recombinant enzyme used for mutagenesis studies are very different. PM III was originally isolated from digestive vacuoles, had a sharp pH optimum of 5.5, and was well-inhibited by pepstatin (5). Three different isolation procedures gave similar results, and there was no detectable contamination by other plasmepsins (although trace contamination by a plasmepsin or another protease cannot be completely excluded). Recombinant protein expressed in Escherichia coli had similar properties (76). Later, recombinant protein was again expressed in E. coli for analysis of site-directed mutants mentioned above but had a broad pH optimum from 5 to 8.5, was poorly inhibited by pepstatin, and was potently inhibited by phenylmethylsulfonyl fluoride (73). A H215A mutant had no activity, but the S35A and H32A mutants were similar to WT. It is hard to reconcile these later results with the earlier data, unless there was a contaminating activity present in some of the samples, perhaps from the enterokinase used to generate mature recombinant enzyme. The existing data do not yet form a coherent picture of the mechanism of action of this unusual aspartic protease ortholog.

**Specificity**

An extensive series of studies has assessed specificity of cleavage of hemoglobin or synthetic peptides using native and recombinant digestive vacuole plasmepsins. The four P. falciparum enzymes and the single enzyme from the three other human parasite species (Plasmodium ovale, Plasmadium vivax, and Plasmadium malariae) as well as enzyme from rodent species (P. berghei and Plasmodium chabaudi) have been studied (4–6, 77–90). All four P. falciparum enzymes are capable of degrading hemoglobin and function at the acidic pH of the digestive vacuole (5). Other degradative proteases such as cathepsin E are not able to degrade native hemoglobin, so this is a special property of the digestive vacuole plasmepsins (91). There are minor differences between species, but activity on synthetic peptide libraries shows a general preference for large hydrophobic residues proximal to the cleavage site on the P (N-terminal) and P' (C-terminal) sides, especially at the P1 and P3 positions, with somewhat broader tolerance at P1' and P3' and wide latitude at P2 and P2'. On native hemoglobin, time course studies using native PM I and PM II revealed an initial cleavage of hemoglobin (αβ, tetramer) on the α chain between Phe^{33} and Leu^{34} (1, 36). Proteolysis proceeded with cleavages at a number of sites on both chains. Specificity of cleavage correlated well with the data just mentioned for synthetic peptides. Experiments using peptides corresponding to the scissile α-helix (helix B) revealed enhanced cleavage by PM II when the helix was extended N-terminally and could then interact with a loop on the PM II molecule (91). A model was put forth wherein the plasmepsin recognizes the beginning of the B helix on the α chain of hemoglobin and perches, waiting for the helix to breathe. The B helix is the weakest link on the protein because it has two helix-disrupting glycines. The protease is in position to cleave the 33–34 peptide bond as soon as the helix opens, helping unravel the tightly wound hemoglobin molecule so that further proteolysis can proceed (Fig. 4B).

**Biosynthesis**

Biosynthesis of digestive vacuole plasmepsins follows a circuitous route. The enzymes are made as transmembranezymogens that traverse the secretory system, reach the parasite surface, are internalized via the cytostome along with their substrate hemoglobin, get delivered to the digestive vacuole membrane, and are then cleaved, releasing the mature enzyme into the vacuolar lumen (92–94) (Fig. 3C).

Maturation is carried out by the digestive vacuole cysteine proteases falcipain-2 and -3 (49). If those enzymes are inhibited, plasmepsin autoprocessing takes place, albeit at a slower rate and at a site 1 amino acid upstream from the normal cleavage site. Structures of P. falciparum PM II, PM III, and PM IV proenzymes as well as those of P. vivax PM IV have been solved (63, 95–97). The proenzyme of each is inactive because the propiece pushes apart the N- and C-terminal lobes of the protease, keeping the catalytic residues too far apart for activity. This differs from mammalian aspartic protease zymogens, for which the propiece binds to the substrate cleft to maintain inactivity until pH-dependent autoactivation can take place.

**Key questions**

- What is the mechanism of PM III? Is His^{32} involved in catalysis? Is PM III even an active enzyme?
- Systems biology of hemoglobin degradation: How do cleavages made by each plasmepsin and by other proteases synergize? Why maintain four plasmepsins in P. falciparum? Why do some parasites amplify the digestive vacuole plasmepsin gene region even further?
- When is heme released during hemoglobin proteolysis, and how is this orchestrated with hemozoin formation?

**Effector protein export: Plasmepsin V**

After invasion, the parasite exports hundreds of proteins into the host RBC. These exported effectors enact a dramatic program of host modification, reconstituting a complex trafficking system in the RBC cytosol and altering the host cell’s rigidity, nutrient permeability, and endothelial binding properties (98, 99). A significant portion of this export program appears dedicated to trafficking families of variable membrane adhesins to the RBC surface, creating adhesin-rich protrusions called “knobs” that mediate binding to the vascular endothelium (Fig. 5) (100). In P. falciparum, around 400 predicted gene products are annotated as likely to be exported (101, 102). Nearly 200 belong to three families of membrane adhesins (~120 rifins, 50 PFEMP1s, and 30 stevors) (101, 103). Many of the remaining predicted proteins have no clear function and no homology to genes outside Plasmodium. We are still just beginning to understand the mechanisms by which Plasmodium manipulates its host through its exported proteins.
PM V is not the only gatekeeper to protein export; several mutated PEXEL reporters are correctly cleaved by PM V but still retained in the parasitophorous vacuole (101, 123). Two non-mutually exclusive models have been put forward to explain this. First, export-destined proteins may contain trafficking information in addition to PEXEL that targets them for export. This information would have to be C-terminal to PEXEL, as the N-terminal sequence is removed by PM V. Exported reporter studies have greatly limited the possible locations of such information. The N terminus of PEXEL proteins, containing the PEXEL motif followed by just 11 amino acids, supports export of a GFP fusion (106, 107). Following PEXEL cleavage, the only detectable sequence conservation is the P2′ residue (largely restricted to Gln, Glu, or Asp). Residues beyond P2′ are important for export, as an inserted PEXEL was not sufficient to re-target the normally vacuole-resident SERA5 to the RBC, but if the subsequent 18 amino acids from the signal sequence, termed the HSP101 and get exported by default, unless they are too tightly folded (129) or contain an N-terminal sequence that prevents chaperone recognition.

The second model posits that following PEXEL cleavage, PM V hands off export-destined cargo to an ER chaperone that usheres it through the export pathway (109). In this model, PM V is required not just for cleavage, but also for some downstream
steps. Tests of this model were attempted with constructs that would create a post-PEXEL N terminus independent of PM V using either an engineered signal peptidase or a fused viral protease; these gave discordant results, with the signal peptidase-generated N terminus unable to support export, whereas the viral protease-generated N terminus did support export (110, 130).

Another avenue for elucidating the post-PM V path is to determine its interacting partners, a task that was carefully undertaken by Danushka et al. (131). They found that PM V interacts with a noncatalytic component of the signal peptidase complex SPC25 and, if cross-linked, with the ER translocon Sec61, its accessory proteins for post-translational import Sec62/63, as well as signal peptidase. They posited that secretory proteins follow one of two distinct paths: either they are cleaved by the canonical signal peptidase complex, or they are recognized and cleaved by a distinct signal-processing complex consisting of PM V and SPC25 (131) (Fig. 6). Perhaps there are chaperones that recognize this complex selectively, although their identity is not apparent at this time. A variant of the chaperone hand-off model is that PM V could be in a subregion of the ER with a direct route to the PTEX translocon at the PM V (110, 132). Subregions of the PVM have recently been described, with each region hosting distinct secretory proteins (133, 134). However, there is no information yet about whether these PVM subregions are fed by distinct regions of the ER.

There is some evidence that PM V additionally functions as a secretory maturase for dense granule proteins. Dense granules are small secretory vesicles that discharge shortlyafter parasite invasion into the parasitophorous vacuole surrounding the parasite. In addition to the canonical PEXEL, PM V cleaves the “relaxed PEXEL” (RXLXXE) of the dense granule protein RESA (101, 117). Following PEXEL cleavage, RESA is diverted to the dense granules of the forming daughter merozoites. When these merozoites re-invade new RBCs, RESA is secreted into the vacuolar lumen and rapidly exported via PTEX into the host cell (124, 125). Inhibition of PM V shortly before egress is rapidly deleterious in newly invaded ring-stage parasites (117). RESA itself is nonessential, and whether PM V cleaves additional dense granule proteins is not yet clear. In T. gondii, the PM V ortholog ASP5 cleaves dense granule proteins at a PEXEL-like motif (135–137). When ASP5 processing is blocked, substrates still traffic to the dense granules but are unable to fulfill their roles in modifying the parasitophorous vacuole or host cell (136). If PM V does act as a dense granule protein maturase in both *Toxoplasma* and *Plasmodium*, perhaps this is its ancestral function, a concept that would be especially interesting given recent findings on the translocon, PTEX. This complex is made up of three core components: an AAA⁺-ATPase, Hsp101; a channel-forming protein, Exp2; and an adaptor protein, PTEX150 (126). Hsp101 is a ubiquitous chaperone that has been co-opted by *Plasmodium* to unfold and thread proteins through the translocon. Exp2, in *Plasmodium* and *Toxoplasma*, forms a nutrient pore to get essential substances such as glucose and amino acids from the host cell (138, 139). This protein has also been deployed by *Plasmodium* for a second function—protein export. To dock Hsp101 to the Exp2 pore for protein export, the organism has come up with a novel adapter, PTEX150 (127). Thus, we suggest that *Plasmodium* has cobbled together a protein export system from mostly preexisting components, and further, it has recruited another preexisting protein, PM V, to prepare proteins for export. It is not at all clear why most exported proteins need to be made as preproteins and processed by PM V co-translationally unless the cleavage motif (PEXEL) is an important component of the export recognition system.

**Specificity**

Unlike the digestive vacuole proteases, PM V has a highly specific recognition sequence, cleaving only after the conserved Leu of the consensus PEXEL sequence RXLXE/Q/D (108, 122, 123). Mutation of the highly conserved PEXEL residue P1 or P3 ablates cleavage (with the notable exception of P1 Ile, which can inconsistently support some PM V cleavage) (101, 106, 107, 140). PM V does not cleave the PNEPs SBP1, PfEMP1, and REX2 (101) or a fluorogenic globin-derived peptide cleaved by PM I–IV (105). Functional PEXELs are found 15–30 amino acids downstream of the signal sequence (141); however, whether this location is required for PM V cleavage has not been reported.
Structure

The structure of the *P. vivax* PM V bound to a peptidomimetic inhibitor has been determined and reveals that PM V largely resembles the digestive vacuole plasmepsins, with a few notable differences (114) (Fig. 7). Like PM I-IV, PM V is produced with a poorly conserved N-terminal extension speculated to be a self-inhibiting prodomain. However, processing of PM V has not been detected (105), and the full-length recombinant protein has been reported to be active (118, 119). As in other plasmepsins, the PM V active site is covered by a flap that may serve to regulate substrate access. The PM V flap is several amino acids longer than the analogous region of the digestive vacuole plasmepsins, a difference that could perhaps underlie PM V’s unique substrate specificity. Along the flap (but not predicted to contact the substrate) is an unpaired Cys, which has been implicated in PM V’s sensitivity to Hg$^{2+}$ (118, 120, 121). Connected directly to the flap is an insert made up of two cysteine pairs folded into a cloverleaf-like structure called a “nepenthesin insert,” which it shares with Nep1 from the pitcher plant *Nepenthesia*. The nepenthesin insert is present in PM V across the genus, but absent from other plasmepsins. Its location adjoined to the flap over the active site tempts us to speculate that the nepenthesin insert may respond to similar environmental condition or binding partner and regulate access to the active site. Alternatively, the nepenthesin insert could be a set distance from the active site and be involved in measuring distance from the N-end of potential substrates (142). No clear hint comes from its ortholog Nep1, a broad-substrate digestive protease present in the low pH of the pitcher plant lumen (143). Another unusual feature is a helix-turn-helix motif, again not present in other plasmepsins. Whereas this is often a nucleic acid-interacting motif, it is not clear what purpose such a motif might have in the ER lumen, where all but the nonessential C-terminal tail of PM V is found (109, 144). Projecting away from the active site of the enzyme is a poorly structured insert whose length and sequence varies among different *Plasmodium* species and isolates from different regions (145, 146); mutagenesis studies on recombinant enzyme have not yet revealed a function for this structure (146). Further work has the potential to both uncover novel parasite biology and also unearth secrets of biochemistry broadly applicable to other enzymes outside of *Plasmodium*.

Key questions

- What do signature features of PM V do (helix-turn-helix motif, nepenthesin loop, unpaired cysteine in the flap)?
- What is the basis of exported protein targeting, and how is PM V involved? Is N-acetylation a required part of this, and is it coordinated with PM V action?
- What are the essential PM V substrates required for parasitophorous vacuole establishment?

Transmission-stage plasmepsins: Plasmepsins VI, VII, and VIII

PM VI, VII, and VIII are expressed only in transmission-stage parasites and have roles in midgut sporozoite development and function (104). They have been studied mostly in the rodent malaria parasite *P. berghei*, where each has been disrupted with no effect in the RBC cycle. PM VI knockout parasites produce oocysts that fail to develop into sporozoites, resulting in a transmission block (147). PM VII can be detected in the cytoplasm of *P. falciparum* zygotes and ookinetes, but its function is not known (148). The protein is not present in *P. falciparum* gametocytes, suggesting that it is produced after fertilization. Knockout has no effect on any stage of the *P. berghei* life cycle (149). PM VIII knockout parasites form oocysts in the mosquito midgut (150). However, there is a drastic decrease in the number of salivary gland and hemolymph sporozoites when PM VIII is absent, due to a defect in egress from oocysts. The few sporozoites produced have a defect in gliding motility. Consequently, transmission of these parasites to the host is blocked. The egress phenotype mirrors that seen with PM X in intraerythrocytic parasites (see below), but mechanistic details for PM VIII function remain to be elucidated. More work is needed to understand the function of these important enzymes.

Key questions

- What are the specific roles and substrates of these proteases?
- Do the inhibitors being developed against other plasmepsins also target the transmission-stage plasmepsins?
- What is the role of other plasmepsins, such as PM X, in the transmission stages?

Egress/invasion plasmepsins: Plasmepsins IX and X

An obvious consequence of the malaria parasite’s intraerythrocytic lifestyle is that it needs to get into the host cell and, when it is finished replicating and dividing, needs to get back out (Fig. 8A). Invasion is a multistep process (151, 152) involving initial low-affinity recognition of the red blood cell by the parasite, reorientation of the invasive merozoite, and discharge of secretory organelles. This allows high-affinity binding to erythrocyte surface proteins and to parasite proteins that the organism has secreted onto the host cell membrane. This is followed by erythrocyte cytoskeletal reorganization and signaling cascades, tight junction formation, actin-mediated entry, and finally resealing once inside. The whole invasion process takes less than a minute. Egress is also a complex phenomenon (153–155). The parasite must porate and disrupt the surrounding parasitophorous vacuolar membrane, disassemble the host cell cytoskeleton, porate, and finally rupture the erythrocyte membrane, which it does explosively, releasing new infective merozoites into the circulation. The egress process takes about 10 min. Proteases play key roles in egress and invasion; in invasion, proteolytic processing is essential for invasion protein function; in egress, there is a proteolytic cascade, triggered by the cGMP-dependent discharge of proteases into the parasitophorous vacuole (154). Recent evidence suggests that aspartic proteases play important roles in both entry and exit from the erythrocyte.

PM IX is expressed in late-stage schizonts and is localized to rhoptries (Fig. 8B), secretory organelles that contain adhesins
for erythrocyte invasion and proteins for setting up the PVM upon invasion (156). This organelle is highly segregated, with the invasion ligands at the apical end (neck) and other proteins at the basal end (bulb). Upon depletion/disruption of *P. falciparum* PM IX, invasion of red blood cells is severely compromised (156, 157). Depletion/disruption of PM IX also blocks cleavage of the rhoptry-associated protein 1 (RAP1) and the apical sushi protein (ASP). Peptides corresponding to the cleavage sites of both proteins are cleaved by recombinant PM IX. The activity was observed at pH 6.4 (157). RON3, a rhoptry protein inserted into the PVM during or just after invasion, is also thought to be a PM IX substrate from inhibitor studies (158). Rhoptry morphogenesis and attachment defects were observed in the PM IX-depleted strain (156). These defects presumably explain the invasion phenotype observed. The substrates of PM IX responsible for the phenotype are still not known, because RAP1 is not essential (159) and ASP is predicted to be nonessential by a piggy bac transposon mutagenesis screen (160). Maturation of PM IX appears to be autocatalytic (158).

PM X is involved in both egress and invasion (156–158). In asexual *P. falciparum* parasites, PM X is localized to small oval-shaped vesicles called exonemes (156). The other protein that has been localized to this organelle is the serine protease subtilisin-like protease 1 (SUB1). PM X processes SUB1 to activate it. Knockdown or chemical inhibition of PM X results in the accumulation of SUB1 precursor (156–158). Mature SUB1 is required for the degradation of both the parasitophorous vacuole and red cell membranes to allow dissemination of merozoites from a mother schizont. To initiate the egress cascade, SUB1 activates cysteine proteases called SERAs and merozoite surface proteins called MSPs (154). Full block of PM X traps parasites within the PVM, whereas partial block allows egress from this membrane but prevents escape from the RBC membrane. Presumably, a higher level of activated SUB1 is required for its effects on the erythrocyte. PM X also processes the surface adhesin sheddase SUB2 as well as erythrocyte binding-like (EBL) and Rh family members that are all involved in invasion (158). In sexual stages of *P. falciparum*, PM X is expressed in gametes, zygotes, and ookinetes and in *P. berghei*, it is implicated by inhibitor studies in egress from gametocytes and mosquito midgut invasion (148, 157). PM X processes the midgut invasion protein cell-traversal protein for ookinetes and sporozoites (CelTOS) (157). Inhibitors also prevent progression from the liver to erythrocytes, although different compounds either block merozoite formation (hence egress of schizonts in hepatocytes (157)) or have an effect on merozoite competence (158).

It is worth noting that compounds used in these studies inhibit both PM IX and PM X. PM IX is not expressed in liver or sexual stages, however, suggesting that action may be specific to PM X in these portions of the life cycle, although some effects through action on another aspartic protease may be suggested by the fact that different small molecules have been reported to have somewhat different effects on mosquito and liver-stage parasites. Recombinant PM X is active at pH 5.5 and can cleave a variety of synthetic peptide substrates, including ones based on SUB1, EBA-175, EBA-181, and Rh2 (156–158). It has a strong preference for cleavage between two hydrophobic residues, not dissimilar from the digestive vacuole plasmepsins, and prefers a polar P2 residue and Glu, Gln, or Asp for P2’ (158). PM X can cleave PM IX substrates, suggesting overlapping specificity (158). PM X is autocatalytic, but in parasites not all of the PM X gets processed; they retain some as proenzyme (66 kDa) or as active 51- and 44-kDa versions (156–158). An ER calcium-binding protein called PfERC is required for PM X maturation in an unknown fashion (161).

In *Toxoplasma gondii*, one aspartic protease called ASP3 is closely related to both PM IX and PM X (9). It is localized in an endosomal compartment (post-Golgi). This protein processes microneme and rhoptry proteins and is implicated in egress and invasion and hence is thought of as a PM IX and PM X chimera (162). Mutations in the conserved Phe344 confer resistance to the small-molecule inhibitor 49c in cultured *Toxo-
plasma and for isolated ASP3, PM IX, or PM X (163). The cleavage sites for ASP3 substrates are similar to the peptide cleavage sites for the PM IX and PM X that were tested, adding to the concept of their relatedness and similar roles in the two organisms. PM V, IX, and X all share a function as secretory organelle protein maturases (Fig. 8B).

Key questions

- What are the key substrates of PM IX required for rhoptry morphogenesis?
- How does PM X cleave and activate the SUB1 precursor that is bound to its propiece?
- Where does PM X interact with and process some microneme and rhoptry proteins? It has only been found in exonemes thus far.

Other aspartic proteases

Four other putative aspartic proteases are encoded in the Plasmodium genome but were not appreciated when the plasmpsins were named (164). MiGS is most homologous to PM V but is expressed in male gametocytes and microgametes (165, 166). It appears to play a role in formation of the secretory osmiophilic bodies of male gametocytes. After secretion onto the surface, it also plays a role in exflagellation of male microgametes that go on to fertilize the female gametes. Like the other plasmpsins, it is predicted to have a classical pepsin-like fold; however, one of the catalytic sites has clearly undergone substantial mutation, with the conserved DTGS mutated to LTNS. Whether MiGS folds in an unexpected way to bring another catalytic residue into the active site, acts as a homodimer, or acts as a pseudoprotease is unclear.

Ddi1 (DNA damage-inducible protease 1) is another aspartic protease with a Plasmodium ortholog. In other eukaryotes, it is important for the cell cycle through ubiquitin/proteasome interactions (167). It has only one catalytic aspartate and homodimerizes to form the active enzyme. In malaria parasites, all that is known is that its gene is refractory to knockout in P. berghei and P. falciparum (160, 168, 169).

SPP is an intramembrane aspartic protease that processes signal peptides after release from secretory proteins in the ER. Early reports based on antibody and inhibitor studies suggested that the Plasmodium ortholog of SPP might be a micronemal protein involved in invasion (170, 171). Further reports, however, instead localized this protein to the ER and demonstrated roles in signal peptide proteolysis and ER stress responses (172–174). More detailed cellular analysis of SPP-selective inhibitor treatment showed inhibition of intraerythrocytic parasite development rather than invasion (172). Heterologous expression studies have confirmed the ability to cleave intramembrane signal peptides (173, 175, 176). Potent SPP inhibitors that kill cultured intraerythrocytic parasites (171–173, 177) and also block liver-stage development (173, 178) have been described. SPP appears to be an attractive drug target.

Finally, a gene present on chromosome 14 (PF3D7_1465600) next to PM VIII and annotated as an aspartic protease (164) has very distant homology to PM VIII, but the predicted protein is missing both catalytic motifs and is unlikely to be an active protease. It is expressed most highly in male gametocytes and may also be expressed in asexual parasites and other life-cycle stages (179). The gene is predicted to be essential in P. falciparum but not in P. berghei from genome-scale mutational analyses (160, 168). Its function is completely unknown.

Key questions

- How does MiGS work in exflagellation? Is it an active enzyme? What are its substrates?
- What is the role of Ddi1 in the parasite? What are associated proteins and substrates?
- Can selective SPP inhibitors be developed? What is the role of SPP in the ER stress response?

Plasmepsins as drug targets

Thousands of inhibitors have been designed against plasmpsins. Additionally, clinically used HIV protease inhibitors such as lopinavir have been investigated in detail, although their clinical antimalarial efficacy is likely to be marginal. The inhibitor literature has been reviewed elsewhere (8, 180, 181) and is beyond the scope of this article. Here, we will instead focus on implications of the biology of plasmpsins for drug development.

Digestive vacuole plasmepsins play an important role in hemoglobin degradation. Knockout lines are markedly impaired in growth both in culture (P. falciparum) (42) and in vivo (P. berghei-rodent model) (43, 44). In fact, the attenuated P. berghei are cleared and can protect from subsequent challenge with heterologous parasites. That being said, knockout parasites are still viable, and an anti-digestive vacuole plasmpsin drug would need a very long half-life to suppress growth over multiple cycles for parasite clearance. It is unlikely that a digestive vacuole plasmpsin-specific agent will come to fruition, although a compound that blocked digestive vacuole plasmps in addition to an essential plasmpsin (CWHM-117 is an example (156)) would likely get an efficacy boost from its action on hemoglobin degradation.

PM V is another interesting enzyme to consider as a target. The process of protein export is essential (124, 125, 138), as presumably is dense granule secretion that helps form the parasitophorous vacuole after invasion, in which PM V likely plays a role (117). Blocking PM V could potentially hit the parasite at two different points in its developmental cycle, which is an advantage for treating an infection that can be asynchronous. Tempering enthusiasm for this target is the observation that PM V must be knocked down nearly completely to have any advantage for treating an infection that can be asynchronous. The implication is that a drug would have to have exceptional potency to be effective. Current recommended EC_{50} values for parasite killing by candidate compounds are in the low nanomolar range. A compound would likely have to have a mid-picomolar k_{i} for PM V to achieve efficacy—not impossible, but a very high bar.

Plasmepsin VI, VII, and VIII are potential drug targets for insect stages of the parasite. A drug against an enzyme in these
stages would not cure a patient but could prevent transmission of the disease. Dosing patients to get a curative concentration in the mosquito is a potential hurdle. Not enough is known about these enzymes to have a clear idea how to move forward. PM VII appears to be dispensable and therefore would be low on the list.

PM IX is a candidate drug target. It is essential for blood-stage parasites (156, 157) and is inhibited by the small-molecule inhibitors 49c and WM382 (157, 158), although both compounds are also potent against PM X. PM X is also essential for blood-stage parasites and can be potently blocked by the dual-inhibitors in vivo using rodent malaria models, and 49c and WM382 also have been shown to interrupt transmission to mosquitoes as well as egress from hepatocytes. The extra-erythrocytic phenotypes have been shown to interrupt transmission to mosquitoes as well as by amino-hydantoins (156–158). Each of these chemotypes is active in vivo using rodent malaria models, and 49c and WM382 also are potent against PM X. PM VI is the next best-studied plasmepsin. Its role in exported effector protein processing is fairly clear, but its function in dense granule protein processing is not well-established. The protein has a number of unusual domains whose functions are not yet clear at this time. Plasmepsins VI–VIII as well as the PM V paralog MiGS play roles in the insect stages; PM X may as well. Studies of these protease activities in the mosquito are just beginning. PM IX and PM X have defined roles in erythrocytic invasion and egress, but their enzymology is not yet defined. Many of these enzymes afford opportunities for antimalarial drug discovery, and we can look forward to exciting new drug candidates in the not too distant future.

**Key questions**

- HIV protease inhibitors like lopinavir kill malaria parasites in culture. What is their killing target? The digestive vacuole plasmepsins, Ddi1, SPP, and hexose transporter PfHT1 have all been proposed (169, 184–188).
- Do PM X inhibitors work in mosquito stages by blocking PM X, and/or do they target other enzymes, such as MiGS or PM VI–VIII?
- Will a drug against a target that is active during just a few hours of the life cycle show sustained efficacy?
- Is hemoglobin digestion a viable target?

**Conclusions**

Plasmepsins participate throughout the complex biology of the malaria parasite (Table 1). The digestive vacuole plasmepsins are the most extensively studied, and we have a reasonable picture of their biosynthesis and roles in hemoglobin degradation. We do not yet understand the mechanism of PM III, with its histidine instead of a canonical aspartate. Plasmepsin V is the next best-studied plasmepsin. Its role in exported effector protein processing is fairly clear, but its function in dense granule protein processing is not well-established. The protein has a number of unusual domains whose functions are not clear at this time. Plasmepsins VI–VIII as well as the PM V paralog MiGS play roles in the insect stages; PM X may as well. Studies of these protease activities in the mosquito are just beginning. PM IX and PM X have defined roles in erythrocytic invasion and egress, but their enzymology is not yet defined. Many of these enzymes afford opportunities for antimalarial drug discovery, and we can look forward to exciting new drug candidates in the not too distant future.

**EuPathDB Accession numbers**

Plasmepsins: I (PF3D7_1407900), II (PF3D7_1408000), III (PF3D7_1408100), IV (PF3D7_1407800, PBANKA_1034400), V (PF3D7_1323500), VI (PF3D7_0311700), VII (PF3D7_1033800), VIII (PF3D7_1465700), IX (PF3D7_1430200), X (PF3D7_0808200); other proteases: MiGS (PF3D7_1234400), Ddi1 (PF3D7_1409300), SPP (PF3D7_1457000), falcipain 2 (PF3D7_1115700), falcipain 3 (PF3D7_1115400), DPAP1 (PF3D7_1116700), aminopeptidase P (PF3D7_1454400), aminopeptidase M1 (PF3D7_1311800), SUB1 (PF3D7_0507500), SUB2 (PF3D7_1136900), TgAsp1 (TGME49_201840), TgAsp2 (TGME49_262940), TgAsp3 (TGME49_246550), TgAsp4 (TGME49_209620), TgAsp5 (TGME49_242720), TgAsp6 (TGME49_272510); other proteins: HDP (PF3D7_1446800), RAP1 (PF3D7_1410400), ASP (PF3D7_0405900), AMA1 (PF3D7_1133400).

**Data availability**

All data are contained within the manuscript.

**Acknowledgments**—We thank Dr. Prasenjit Bhaumik (Indian Institute of Technology, Mumbai) for helpful comments and Dr. Robert Potter (Washington University) for help with phylogenetic analysis. We acknowledge PlasmoDB as a source for analysis of genes discussed herein.

References


JBC REVIEWS: Malaria parasite plasmepsins


A druggable secretory protein mature of *Toxoplasma* essential for invasion and egress. *Elife* 6, e27480 CrossRef Medline


